publication . Article . 2017

use of parecoxib by continuous subcutaneous infusion for cancer pain in a hospice population

Armstrong, Peter; Wilkinson, Pauline; McCorry, Noleen;
Open Access
  • Published: 01 Sep 2017 Journal: BMJ Supportive & Palliative Care, volume 8, pages 25-29 (issn: 2045-435X, eissn: 2045-4368, Copyright policy)
  • Publisher: BMJ
  • Country: Bangladesh
Abstract
<jats:sec><jats:title>Objectives</jats:title><jats:p>To characterise the use of the parenteral non-steroidal anti-inflammatory drug parecoxib when given by continuous subcutaneous infusion (CSCI) in a hospice population. Clinical experience suggests parecoxib CSCI may be of benefit in this population, but empirical evidence in relation to its safety and efficacy is lacking.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective chart review of patients with a cancer diagnosis receiving parecoxib CSCI from 2008 to 2013 at the Marie Curie Hospice, Belfast. Data were collected on treatment regime, tolerability and, in patients receiving ...
Subjects
free text keywords: Medicine (miscellaneous), Oncology(nursing), Medical–Surgical, General Medicine, Tolerability, Cancer pain, Parecoxib, medicine.drug, medicine, Anesthesia, Retrospective cohort study, Opioid, Adverse effect, business.industry, business, Oral administration, Population, education.field_of_study, education, Short Report, 1506, cancer, pain, symptoms and symptom management
Related Organizations
22 references, page 1 of 2

1 World Health Organisation. WHO’s cancer pain ladder for adults. 1986 http://www.who.int/cancer/palliative/painladder/en/ (accessed Jan 2017).

2 García Rodríguez LA, Barreales Tolosa L Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007;132:498–506. 10.1053/j.gastro.2006.12.007 17258728 [OpenAIRE] [PubMed] [DOI]

3 Pfizer Limited 2015, January 2-last update, Summary of Product Characteristics. Dynastat 40mg powder for solution for injection. http://www.medicines.org.uk (accessed Jan 2017).

4 Kenner DJ, Bhagat S, Fullerton SL Daily subcutaneous parecoxib injection for cancer pain: an open label pilot study. J Palliat Med 2015;18:366–72. 10.1089/jpm.2014.0249 25695199 [OpenAIRE] [PubMed] [DOI]

5 De Conno F, Zecca E, Martini C, et al Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report. J Pain Symptom Manage 1994;9:119–21. 10.1016/0885-3924(94)90164-3 8021534 [OpenAIRE] [PubMed] [DOI]

6 Blackwell N, Bangham L, Hughes M, et al Subcutaneous ketorolac--a new development in pain control. Palliat Med 1993;7:63–5. 10.1177/026921639300700110 8287202 [OpenAIRE] [PubMed] [DOI]

7 Myers KG, Trotman IF Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Postgrad Med J 1994;70:359–62. 10.1136/pgmj.70.823.359 8016008 [OpenAIRE] [PubMed] [DOI]

8 Hall E Subcutaneous diclofenac: an effective alternative?Palliat Med 1993;7:339–40.

9 Tang J, Li S, White PF, et al Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 2002;96:1305–9. 10.1097/00000542-200206000-00007 12170040 [OpenAIRE] [PubMed] [DOI]

10 Alkhenizan A, Librach L, Beyene J NSAIDs: are they effective in treating cancer pain?Eur J Palliat Care 2004;11:5–8.

11 Mitchell K, Pickard J, Herbert A, et al Incidence and causes for syringe driver site reactions in palliative care: A prospective hospice-based study. Palliat Med 2012;26:979–85. 10.1177/0269216311428096 22084491 [OpenAIRE] [PubMed] [DOI]

12 Dickman A, Schneider J The syringe driver: continuous subcutaneous infusions in palliative care. 2nd edition Oxford: Oxford University Press, 2011.

13 Hawkins C, Hanks GW The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature. J Pain Symptom Manage 2000;20:140–51. 10.1016/S0885-3924(00)00175-5 10989252 [PubMed] [DOI]

14 Clive DM, Stoff JS Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984;310:563–72. 10.1056/NEJM198403013100905 6363936 [PubMed] [DOI]

15 British Medical Association and Royal Pharmaceutical Society. British national formulary. 72nd ed London: BMJ Group and Pharmaceutical Press, 2016.

22 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue